The arrival of Retatrutide ZPHC, at a concentration of 120mg, is sparking considerable interest within the healthcare community. This groundbreaking dual GIP and GLP-1 agonist medication suggests to offer significant improvements in body shedding compared to previous therapies. Initial research t